Millennium Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Millennium Management’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,280	Closed	-$14K	–	7144
2023 Q1	$14K	Buy	+13,280	New	+$25.2K	﹤0.01%	5962
2022 Q2	–	Sell	-461	Closed	-$4K	–	7917
2022 Q1	$4K	Sell	461 -614	-57%	-$5.84K	﹤0.01%	6812
2021 Q4	$12K	Buy	1,075 +167	+18%	+$2.4K	﹤0.01%	6643
2021 Q3	$16K	Buy	908 +386	+74%	+$6.37K	﹤0.01%	6673
2021 Q2	$10K	Sell	522 -1,460	-74%	-$27.8K	﹤0.01%	6445
2021 Q1	$49K	Buy	+1,982	New	+$59.4K	﹤0.01%	5778
2018 Q1	–	Sell	-11	Closed	-$163K	–	4345
2017 Q4	$163K	Sell	11 -9	-45%	-$208K	﹤0.01%	3576
2017 Q3	$547K	Sell	20 -2	-9%	-$61.5K	﹤0.01%	2801
2017 Q2	$1.14M	Buy	22 +21	+2,100%	+$1.15M	﹤0.01%	2380
2017 Q1	$48K	Sell	1 -7	-88%	-$566K	﹤0.01%	3390
2016 Q4	$616K	Buy	8 +6	+300%	+$536K	﹤0.01%	2561
2016 Q3	$218K	Hold	2	–	–	﹤0.01%	2948
2016 Q2	$166K	Buy	+2	New	+$235K	﹤0.01%	2939
2015 Q4	–	Sell	-1	Closed	-$173K	–	3975
2015 Q3	$173K	Buy	+1	New	+$234K	﹤0.01%	3158

Other funds holding NVIV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Millennium Management's NVIV Position: Q2 2023 in Review

Millennium Management sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2023, closing a stake of 13,280 shares — an estimated $14K sold.

Millennium Management first reported a position in NVIV in Q3 2015 and held it in 14 quarters. The position peaked at $1.14M in Q2 2017. 15 funds tracked by Wall St. Rank hold NVIV as of Q2 2023.

Millennium Management reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2023 after selling out during the quarter.
Millennium Management sold 13,280 InVivo Therapeutics Holdings Corp shares in Q2 2023, an estimated $14K.
Millennium Management first reported a position in InVivo Therapeutics Holdings Corp in Q3 2015 and held it in 14 quarters.
Millennium Management's InVivo Therapeutics Holdings Corp position peaked at $1.14M in Q2 2017.
15 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.